EP1617872A4 - Procedes et compositions permettant de renforcer une reponse immune - Google Patents

Procedes et compositions permettant de renforcer une reponse immune

Info

Publication number
EP1617872A4
EP1617872A4 EP04775877A EP04775877A EP1617872A4 EP 1617872 A4 EP1617872 A4 EP 1617872A4 EP 04775877 A EP04775877 A EP 04775877A EP 04775877 A EP04775877 A EP 04775877A EP 1617872 A4 EP1617872 A4 EP 1617872A4
Authority
EP
European Patent Office
Prior art keywords
enhancing
compositions
methods
immune response
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04775877A
Other languages
German (de)
English (en)
Other versions
EP1617872A2 (fr
Inventor
Richard L Miller
Mark A Tomai
Ross M Kedl
Isidro Angelo E Zarraga
Ronnie Ortiz
James D Stoesz
Paul D Wightman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/640,904 external-priority patent/US7427629B2/en
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of EP1617872A2 publication Critical patent/EP1617872A2/fr
Publication of EP1617872A4 publication Critical patent/EP1617872A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
EP04775877A 2003-04-10 2004-04-09 Procedes et compositions permettant de renforcer une reponse immune Withdrawn EP1617872A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US46214003P 2003-04-10 2003-04-10
US10/640,904 US7427629B2 (en) 2002-08-15 2003-08-14 Immunostimulatory compositions and methods of stimulating an immune response
US51525603P 2003-10-29 2003-10-29
US53370303P 2003-12-31 2003-12-31
US54542404P 2004-02-18 2004-02-18
US54554204P 2004-02-18 2004-02-18
PCT/US2004/011085 WO2005001022A2 (fr) 2003-04-10 2004-04-09 Procedes et compositions permettant de renforcer une reponse immune

Publications (2)

Publication Number Publication Date
EP1617872A2 EP1617872A2 (fr) 2006-01-25
EP1617872A4 true EP1617872A4 (fr) 2011-09-07

Family

ID=34923557

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04775877A Withdrawn EP1617872A4 (fr) 2003-04-10 2004-04-09 Procedes et compositions permettant de renforcer une reponse immune

Country Status (5)

Country Link
EP (1) EP1617872A4 (fr)
JP (1) JP2007514644A (fr)
AU (1) AU2004252409A1 (fr)
CA (1) CA2521662A1 (fr)
WO (1) WO2005001022A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006007433A1 (de) * 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
JP2010507361A (ja) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
WO2009030254A1 (fr) 2007-09-04 2009-03-12 Curevac Gmbh Complexes d'arn et de peptides cationiques pour transfection et immunostimulation
CN101932707B (zh) 2008-01-31 2013-08-21 库瑞瓦格有限责任公司 作为免疫刺激剂/佐剂的式(I)(NuGlXmGnNv)a的核酸及其衍生物
WO2010037408A1 (fr) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprenant un arnm complexé et un arnm nu pour déclencher ou augmenter une réponse immunostimulante chez un mammifère et utilisations de ladite composition
MX2011004249A (es) 2008-10-24 2011-07-20 Glaxosmithkline Biolog Sa Derivados de imidazoquinolina lipidados.
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US8968746B2 (en) 2010-07-30 2015-03-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2013113326A1 (fr) 2012-01-31 2013-08-08 Curevac Gmbh Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide
CA2915728A1 (fr) 2013-08-21 2015-02-26 Thomas Kramps Vaccin contre le virus respiratoire syncytial
EP3065741B1 (fr) * 2013-11-05 2021-09-22 3M Innovative Properties Company Formulations d'injection a base d'huile de sesame
CA2936286A1 (fr) 2014-04-01 2015-10-08 Curevac Ag Complexe cargo de support polymere a utiliser comme agent immunostimulant ou comme adjuvant
CA2998995A1 (fr) 2015-09-29 2017-04-06 Astrazeneca Aktiebolag Composes conjugues de l'adenine et leur utilisation comme adjuvants de vaccins
JP6769976B2 (ja) 2015-10-07 2020-10-14 大日本住友製薬株式会社 ピリミジン化合物
SG11201802769RA (en) 2015-10-29 2018-05-30 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
KR102590454B1 (ko) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
CN112839673A (zh) 2018-07-23 2021-05-25 日本国立感染症研究所所长代表之日本国 包含流感疫苗的组合物
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386757A2 (fr) * 1989-03-09 1990-09-12 The Johns Hopkins University School Of Medicine Esters de polyphospho biodégradables
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
WO1997013499A1 (fr) * 1995-10-11 1997-04-17 The University Of British Columbia Formulations de liposomes a base de mitoxantrone
WO2000040228A2 (fr) * 1999-01-08 2000-07-13 3M Innovative Properties Company Formulations et procedes utilises pour le traitement des etats pathologiques des muqueuses au moyen d'un modificateur de la reponse immunitaire
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
WO2002046749A2 (fr) * 2000-12-08 2002-06-13 3M Innovative Properties Company Procede de criblage permettant d'identifier des composes qui induisent de maniere selective la production d'interferon alpha
CN1377648A (zh) * 2002-04-23 2002-11-06 四川大学 皮肤局部用咪喹莫特或其衍生物脂质体及其制备方法和用途
WO2004032829A2 (fr) * 2002-08-15 2004-04-22 3M Innovative Properties Company Compositions immunostimulantes et procedes de stimulation d'une reponse immune
WO2004060967A1 (fr) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Procedes de formation d'hydrogels au moyen de compositions de thiosulfonate et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7998091A (en) * 1990-05-17 1991-12-10 Harbor Medical Devices, Inc. Medical device polymer
US6486214B1 (en) * 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US6518280B2 (en) * 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386757A2 (fr) * 1989-03-09 1990-09-12 The Johns Hopkins University School Of Medicine Esters de polyphospho biodégradables
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
WO1997013499A1 (fr) * 1995-10-11 1997-04-17 The University Of British Columbia Formulations de liposomes a base de mitoxantrone
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
WO2000040228A2 (fr) * 1999-01-08 2000-07-13 3M Innovative Properties Company Formulations et procedes utilises pour le traitement des etats pathologiques des muqueuses au moyen d'un modificateur de la reponse immunitaire
WO2002046749A2 (fr) * 2000-12-08 2002-06-13 3M Innovative Properties Company Procede de criblage permettant d'identifier des composes qui induisent de maniere selective la production d'interferon alpha
CN1377648A (zh) * 2002-04-23 2002-11-06 四川大学 皮肤局部用咪喹莫特或其衍生物脂质体及其制备方法和用途
WO2004032829A2 (fr) * 2002-08-15 2004-04-22 3M Innovative Properties Company Compositions immunostimulantes et procedes de stimulation d'une reponse immune
WO2004060967A1 (fr) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Procedes de formation d'hydrogels au moyen de compositions de thiosulfonate et leurs utilisations

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"The Merck Index, An encyclopedia of chemicals, drugs, and biologicals 13th Edition", 1 January 2001, MERCK & CO., INC, XP007914381 *
ALEXIOU C ET AL: "LOCOREGIONAL CANCER TREATMENT WITH MAGNETIC DRUG TARGETING", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, vol. 60, no. 23, 1 December 2000 (2000-12-01), pages 6641 - 6648, XP001063184, ISSN: 0008-5472 *
HULAND EDITH ET AL: "In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 121, no. 5, 1995, pages 285 - 290, XP008140263, ISSN: 0171-5216 *
LAMBERT D M: "Rationale and applications of lipids as prodrug carriers", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 11, no. S2, 1 January 2000 (2000-01-01), pages S15 - S27, XP002245016, ISSN: 0928-0987, DOI: 10.1016/S0928-0987(00)00161-5 *
MUI B ET AL: "Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, WILLIAMS AND WILKINS CO, vol. 298, no. 3, 1 September 2001 (2001-09-01), pages 1185 - 1192, XP002228992, ISSN: 0022-3565 *
PACIOTTI G F ET AL: "Comparison of the toxicity and pharmacokinetics of neat and colloidal good bound TNF", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 40, 1 March 1999 (1999-03-01), pages 585, XP001537146, ISSN: 0197-016X *
WANG HUAN ET AL: "Comparison of Transdermal Diffusion in vitro of Imiquimod in Liposomes and Cream", ZHONGGUO YIYAO GONGYE ZAZHI - CHINESE JOURNAL OF PHARMACEUTICALS, SHANGHAI YIYAO GONGYE YANJIUYUAN, SHANGHAI, CN, vol. 34, no. 2, 1 February 2003 (2003-02-01), pages 73 - 75, XP008156372, ISSN: 1001-8255 *
WANG HUAN ET AL: "Preparation Technology of Imiquimod Chitosan Nanoparticle Optimized by Orthogonal Test", ZHONGGUO YAOSHI - CHINA PHARMACIST, YAOWU LIUXINGBINGXUE ZAZHISHE, HUBEI, CN, vol. 5, no. 7, 1 July 2002 (2002-07-01), pages 432 - 433, XP008156371, ISSN: 1008-049X *

Also Published As

Publication number Publication date
JP2007514644A (ja) 2007-06-07
CA2521662A1 (fr) 2005-01-06
WO2005001022A2 (fr) 2005-01-06
AU2004252409A1 (en) 2005-01-06
EP1617872A2 (fr) 2006-01-25
WO2005001022A3 (fr) 2005-09-15

Similar Documents

Publication Publication Date Title
EP1729768A4 (fr) Formulations modificatrices de reponse immunitaire et procedes correspondants
EP1835915A4 (fr) Formulations de modificateur de reaction immunitaire et procedes associes
EP1812031A4 (fr) Compositions et procedes de modification de biomolecules
ATE402934T1 (de) Malonamidderivate als gamma-secretaseinhibitoren
ATE478868T1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
EP1686981A4 (fr) Compositions et procedes de radiotherapie et de chimiotherapie combinatoires
EP1701725A4 (fr) Methodes et compositions
IS8006A (is) Setin pýrimidínón
NO2014013I2 (no) Linaclotide
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
DE602004020318D1 (de) Abbildungseinrichtung
EP1612464A4 (fr) Thermostat
DE602004022101D1 (de) solches system
DE602004024888D1 (de) Multipartikeln
DK1687725T3 (da) Sikkert betalingssystem
EP1896050A4 (fr) Procedes et compositions peptidiques lkktet et/ou lkktnt
DE502004004657D1 (de) Transversalflussmaschine
MA28582B1 (fr) Composes de thieno-pyridinone et procedes de traitement associes
DE502004006055D1 (de) 6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren
DE602004021269D1 (de) 5-arylpyrimidine als anti-krebs-mittel
ATA17862003A (de) Belag aus belagsplatten
DE602004018858D1 (de) Emulsionszusammensetzung
EP1991237A4 (fr) Procedes et compositions chimioprotecteurs
DE602004010464D1 (de) Videoverarbeitung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110810

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/48 20060101ALI20110804BHEP

Ipc: A61F 2/76 20060101ALI20110804BHEP

Ipc: A61K 47/00 20060101ALI20110804BHEP

Ipc: A61F 2/06 20060101ALI20110804BHEP

Ipc: A61P 37/00 20060101ALI20110804BHEP

Ipc: A61F 2/24 20060101ALI20110804BHEP

Ipc: A61K 45/00 20060101AFI20110804BHEP

17Q First examination report despatched

Effective date: 20121108

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20190123